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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
 Opioid substitution therapy halves clients’ drug-related death-rate. 
 Yet, age-related increases drug-related and methadone-specific deaths persist. 
 Opioid-cohorts lack substantial data on prescribed daily-dose of methadone. 
WHAT THIS STUDY ADDS   
 Validated simple rules for recovery of prescribed daily-dose of methadone. 
 Baseline daily-dose of prescribed methadone available for 73% of Scotland’s 
methadone-client cohort (2009-2015).  
 Top quintile for prescribed daily-dose (> 90 mg per day) associated with increased 
hazard for methadone-specific death versus 50-70 mg; three times greater risk of 
methadone-specific death at 45+ years versus 25-34 years; females may be at 
greater risk of methadone-specific death.  
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Abstract  
 
Background: As methadone-clients age, their drug-related death (DRD) risks increase, more than 
doubling at 45+ years for methadone-specific DRDs. 
Methods: Using Community Health Index (CHI) numbers, mortality to 31 December 2015 was 
ascertained for 36,347 methadone-prescription-clients in Scotland during 2009-2015. Cohort-entry, 
quantity of prescribed methadone and daily-dose (actual or recovered by effective, simple rules) 
were defined by clients’ first CHI-identified methadone-prescription after 30 June 2009 and used in 
proportional hazards analysis. As custodian of death-records, National Records of Scotland identified 
non-DRDs from DRDs. Methadone-specific DRD means methadone was implicated but neither 
heroin nor buprenorphine. 
Results: The cohort’s 192,928 person-years included 1857 non-DRDs; 1323 DRDs (42%), 546 being 
methadone-specific DRDs. Actual/recovered daily-dose was available for 26,533 (73%) clients who 
experienced 420 methadone-specific DRDs. Top quintile for daily-dose at first CHI-identified 
methadone prescription was >90mg. 
Age 45+ years at cohort-entry (hazard ratio versus 25-34 years: 3.1, 95% CI: 2.4-4.2), top quintile for 
baseline daily-dose of prescribed methadone (versus 50-70 mg: 1.9, 1.1-3.1) and being female (1.3, 
1.0-1.6) significantly increased clients’ risk of methadone-specific DRD. 
Conclusions: Extra care is needed when methadone daily-dose exceeds 90mg. Females’ higher risk 
for methadone-specific DRD is new; and needs validation. Further analyses of prescribed daily-dose 
linked to mortality for large cohorts of methadone-clients are needed internationally; together with 
greater pharmacodynamic and pharmacokinetic understanding of methadone by age and gender. 
Balancing age-related risks is challenging for prescribers who manage chronic opiate dependency 
against additional uncertainty about the nature, strength and pharmacological characteristics of 
drugs from illegal markets.  [249 words] 
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Introduction 
By the 1990s, UK’s heroin injector epidemics of the early 1980s were being countered by 
opioid substitution therapy, primarily methadone, which not only reduced drug-related 
deaths (DRDs) [1, 2] but also blood-borne virus transmissions and criminality [3, 4]. 
Scotland’s methadone-prescription cohort [5] includes many who are former injectors, of 
whom at least half will be hepatitis C virus carriers [6, 7]; most smoke; misuse of alcohol, 
psychiatric and physical co-morbidities are also not uncommon [8, 9].  
Despite the remarkable fall in UK’s DRD-rate per 1 million defined daily doses of methadone 
in the early 21st century [1], the present decade has seen sharply increased numbers of 
opioid-related deaths [10]. The UK’s increase was anticipated by evidence-syntheses [11-13] 
and by national record-linkage studies of “virtual cohorts” of opioid-dependent clients [3, 
14]. Both forewarned about demographic influences (gender; age-group) on DRD-rates, 
including a strong gender by age-group interaction in DRD-risk for opioid users [14, 5]. 
Discovering that females’ advantage, in terms of lower DRD-risk, diminished with age [14] is 
important for risk-prediction [15] but was unrecognized in early systematic reviews [16]. 
We became concerned about a possible role for prescribed methadone in Scotland’s rise in 
methadone deaths in the second decade of the 21st century [5].   Indeed, Scotland’s 2009-
2013 methadone-prescription cohort demonstrated that clients’ risk of methadone-specific 
DRD increased more strikingly with age than for all DRDs [5]. Quickly, the cohort of opioid 
users in England’s 2005-09 National Drug Treatment Management System was used to 
validate the Scottish results [17]. This English record-linkage cohort could adjust for a triad 
of major behavioural risk-factors (injector-status, misuse of alcohol, misuse of 
benzodiazepines) but lacked information on the prescribed quantity or daily-dose of 
methadone. Synthesis of the two UK studies suggested that the risk of methadone-specific 
DRD tripled by 45+ years of age (95% CI: 3.0 to 4.7) compared with 25-34 years [17].  
Meanwhile, based on 87 DRDs in a primary care cohort, Hickman et al. [18] considered 
confounding between the choice of opioid substitution therapy (methadone versus 
buprenorphine) and the client’s age-group or number of co-morbidities, both of which are 
potentially implicated in methadone-specific DRDs [5, 17, 19-22].  
Internationally, there is a dearth of information on the daily-dose of prescribed methadone 
for large cohorts of opioid-dependent clients [15, 16].  
Our aim is to provide alternative proportional hazards (PH) analysis for methadone-specific 
DRDs in Scotland’s 2009-2015 methadone-prescription cohort based on: 
i) clients’ gender, age-group at accrual, prescription-source and baseline quintile 
for quantity (qQs) of prescribed methadone; OR 
ii) clients’ gender, age-group at accrual, prescription-source and baseline quintile 
for daily-dose (dQs) of prescribed methadone. 
 
  
 
4 
 
Methods 
Definitions: drug-related deaths 
We applied the UK harmonized definition of DRD [23].  National Records of Scotland [10] 
provided information on the opioid-specificity of Scotland’s DRDs: 
methadone-specific DRDs: methadone was implicated in DRD but neither heroin/morphine 
nor buprenorphine implicated;  
heroin-specific DRDs: heroin/morphine was implicated in DRD but neither methadone nor 
buprenorphine implicated; and  
heroin-methadone DRDs: methadone and heroin/morphine both implicated in DRD but 
buprenorphine was not implicated. 
In appraising which drugs are implicated as causal factors in any DRD and which, although 
present, probably did not contribute, Scotland’s pathologists are supported by having a 
national protocol for toxicological testing at forensic autopsies. 
Scotland’s Community Health Index (CHI) 
Scotland’s CHI is a register of all patients in National Health Service (NHS) Scotland, 
Scotland’s publicly-funded healthcare system. From birth, patients are identified by a 10-
digit CHI-number, usually the patient’s date of birth (DDMMYY) followed by four digits: two 
randomly generated, the third identifying gender (odd for males), and the fourth a check-
digit. The CHI-numbers are key to Scotland’s trusted record-linkage [24], not least because 
deaths and hospitalizations are CHI-identified. 
Scotland’s methadone-prescription-client cohort for 2009-2015: data-sources and linkage  
Methadone prescriptions for opioid substitution therapy fall within a specific classification 
category in Scotland’s National Prescribing Information System [25]: most are CHI-identified, 
see Figure 1. All give quantity of methadone prescribed and number of instalments by which 
the prescribed quantity is issued, as both are required for the reimbursement of 
pharmacists. Daily-dose of prescribed methadone is not routinely available in electronic 
format [5, 26]. But daily-dose of prescribed methadone is available electronically for a 
subset of GP-prescriptions; and was extracted by Scotland’s Information Services Division 
using Natural Language Programs applied to GPs’ electronic messaging [26].  
Instalment dispensing is different in Scotland: on regular GP-prescriptions, any drug is 
allowed and can be for any duration, although good practice suggests a limit of 28 days. In 
England, instalment prescriptions are for a maximum of 14 days and only allow Schedule 2 
Controlled Drugs under the Misuse of Drugs Act 1971. England’s 14-day limit means that 
quantities of prescribed methadone as large as in Scotland are unlikely. 
To define Scotland’s methadone-prescription-client cohort for 2009-2015, nearly 3 million 
methadone prescriptions during 1 July 2009 to 30 June 2015 were assessed for linkage to 
Scotland’s mortality records to 31 December 2015. As all deaths are CHI-identified, 
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prescriptions’ CHI-number was used for this exact linkage. The CHI-number was also used to 
link serial CHI-identified methadone-prescriptions for the same client.  
For CHI-indexed methadone-prescriptions, we obtained: client’s gender, age in completed 
years at 1 July of prescription-year (enabling current age-group to be used in a sensitivity 
analysis); prescription-date (when missing, the later re-imbursement date was used [5]); re-
imbursement-date; prescription-source (GP; other-source); quantity of prescribed 
methadone per prescription; number of instalments per prescription; daily-dose of 
prescribed methadone (if extractable by Natural Language Program from GPs’ electronic 
messaging [5, 26]); full date of death; whether underlying cause of death was non-DRD or 
DRD; and DRDs’ opioid-specificity.  
We defined Scotland’s 2009-2015 methadone-prescription-client cohort as: clients with one 
or more CHI-identified methadone-prescription during 1 July 2009 to 30 June 2015. The 
client’s first CHI-identified methadone-prescription during 1 July 2009 to 30 June 2015 
defined cohort-entry or accrual date, baseline quantity (also daily-dose) of prescribed 
methadone and age-group at accrual (< 25 years, 25-34, 35-44, 45+ years).  
As full date of death is potentially identifying, approval by Scotland’s Public Benefit and 
Privacy Panel for this study required that all computations were within the Usher Institute 
safe-haven.  
Exclusion criteria 
Four types of data-checking were undertaken. First, survival time from the date of CHI-
identified clients’ baseline methadone-prescription was computed: negative survival times 
were checked for evidence of incorrect linkage. Secondly, wide outer bounds were defined 
for four variables, see below: CHI-identified prescriptions falling outside of any of these 
outer bounds were excluded as widely implausible. Third, as before [5] and on account of 
substitution of re-imbursement date for missing prescription-dates, we added 60 days to all 
CHI-identified survival intervals to ensure positivity: any residual negative times resulted in 
client-exclusion. Finally, a plausible upper bound of 69 years was set for age at cohort-entry 
for clients receiving methadone-substitution: breach of this upper bound resulted in client-
exclusion. 
Incorrect linkage: Computing time in days from the date of the client’s baseline CHI-
identified methadone-prescription to the earlier of death-date or 31 December 2015,  
identified 63 negative survival times. On cross-checking, Information Services Division 
confirmed only seven (hereafter deleted) were linked incorrectly.  
Wide outer bounds: CHI-identified methadone-prescriptions in 2009-2015 were excluded if 
any of the following applied on a per-prescription basis: 
i) quantity prescribed: < 5 mg or >12,000 mg; 
ii) instalments: <1 or >84; 
iii) daily-dose: <1 mg or >300 mg;  
iv) age-in-prescription-year: <5 years or >79 years. 
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The analysis file was thereby reduced by 764 CHI-identified methadone-prescriptions 
(0.04%) to 1,931,326; clients by 163 to 36,444; deaths by 37, see Figure 1.  
Ensuring positivity: As in an earlier analysis [5], because re-imbursement date was 
substituted for missing prescription-date, 60 days were added to all survival times. Positivity 
was assured for all except for five CHI-identified clients, who were excluded.  
Plausible upper bound for age at cohort-entry: Ninety-two CHI-identified clients were 
excluded because age at cohort-entry was older than 69 years. 
The two checks above together excluded 97 CHI-identified clients: 52/97 had died; 2/52 
were DRDs. There remained 36,347 CHI-identified methadone-prescription clients. 
Simple rules for establishing daily-dose: derivation and validation 
For this paper, we devised and verified simple rules for recovery of daily-dose from quantity 
of prescribed methadone and number of instalments, see APPENDIX1. 
Simple rules (hereafter, recovery-rules) were devised for establishing daily-dose from 
quantity of methadone prescribed and number of instalments at first CHI-identified 
prescription. Not every instalment number had an acceptable rule, see below. Recovery-
rules were derived for CHI-identified clients who had most recently joined the cohort so that 
our derivation sub-cohort comprised: 
a) clients from the 2009-2013 cohort [5] who received one or more CHI-identified 
methadone prescription after 30 June 2013 and were alive after 31 December 2013 – their 
accrual-date to the derivation sub-cohort was the later of 1 January 2014 and date of their 
sub-cohort-qualifying first CHI-identified methadone-prescription after 30 June 2013; and  
b) new clients, not part of the 2009-2013 cohort [5], who received one or more CHI-
identified methadone-prescriptions after 30 June 2013 and whose accrual-date was the 
date of their qualifying first CHI-identified methadone-prescription after 30 June 2013. 
Conditional on number of instalments, a recovery-rule would be accepted if it correctly 
recovered at least 75% of the actual daily-doses in clients’ accrual-month within the 
derivation sub-cohort. Our performance criteria were met when number of instalments for 
issuing the prescription was 4, 7, 14, 21, 28, 35, 42 or 56, see APPENDIX1; and verified for 
Scotland’s 2009-2015 methadone-prescription cohort. For these listed instalment numbers, 
excepting 4 and 7, performance criteria were met by simply dividing quantity by number of 
instalments; the recovery-rules for 4 and 7 have an additional check-step. All accepted rules 
were then applied to recover daily-dose at cohort-entry for CHI-identified clients. 
Key covariates, including quintiles for daily-dose of prescribed methadone 
Key covariates were: prescription source (GP versus other-prescriber), gender (female 
versus male) and age-group at cohort-entry (< 25 years, 25-34, 35-44, 45+ years). In addition 
[5], quintile for quantity of prescribed methadone at first CHI-identified prescription (qQ) 
was available for all clients.  
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For 26,533 (73%) clients, recovery-rules allowed quintile for daily-dose of prescribed 
methadone at first CHI-identified prescription (dQ) to be analysed. Quintiles partition clients 
into fifths according to prescribed daily-dose: from the 20% receiving the lowest fifth of 
baseline prescribed daily-doses (dQ1) to the top 20% of prescribed daily-doses of 
methadone (dQ5). Using quintile-indicators allows the association between HR and 
increasing baseline prescribed daily-dose to be made explicit in PH regression analysis. 
Statistical analysis 
After documenting the impact of exclusion criteria on prescriptions, clients and deaths, we 
summarize the performance of recovery-rules for daily-dose for Scotland’s 2009-2015 
methadone-prescription cohort. 
Next, for each covariate-level, we provide DRD-rates and methadone-specific DRD-rates for 
the cohort as a whole; and when restricted to clients with actual or recovered daily-dose at 
first CHI-identified prescription. 
Using PH regression analysis, we assess how steeply hazard ratios (HRs) increase by age-
group at accrual for methadone-specific DRDs; and how influential - based on regression 
chi-squares on four degrees of freedom (dfs) - are dQs versus qQs. Adjusted HRs and 95% 
confidence intervals are estimated simultaneously, relative to each covariate’s baseline-
category as shown in tables. APPENDIX2 includes corresponding PH analyses for all DRDs 
which, unlike methadone-specific DRDs, require gender by age-group interaction to be 
taken into account. All analyses were performed using STATA v15.1; STATA’s stcox was used 
for PH analysis. 
Sensitivity analysis 
APPENDIX3 includes three type of sensitivity analysis. First, rather than age-group at cohort-
entry, we fitted time-updated age-group since a single transition to an older age-group 
could have occurred. The second analysis focuses on GP-clients solely as GP-prescriptions 
alone were the basis for our recovery-rules.  Thirdly, the key PH analysis for methadone-
specific DRDs which incorporated dose-quintiles was repeated separately: a) CHI-identified 
clients who entered the Scotland’s 2009-2015 methadone-prescription cohort during July to 
December 2009 (mainly as prevalent clients; and b) CHI-identified clients who entered the 
cohort during 2010 and 30 June 2015 (including relatively more incident clients in their 
methadone titration-phase.  
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Results  
Exploratory data analysis 
Exclusions: After exclusion-steps (see Figure 1), the 5th and 95th percentiles for all CHI-
identified methadone-prescriptions were:  for quantity, 140 and 2,970 mg, mean of 1,221 
mg (sd 1,025); for number of instalments, 1 and 84, mean of 13.3 instalments (sd  9.6); for 
actual daily-dose, 16 and 120 mg, mean of 64 mg (sd 34) – available for only 736,153 (38%) 
of all CHI-identified prescriptions, but for 51% of 1,429,863 CHI-identified GP-prescriptions. 
Recovery rules and descriptive statistics: Eight accepted recovery rules for daily-dose at 
cohort-entry were generally of the form “quantity prescribed divided by D(i)” where the 
value for divisor D(i) depended on (i), the number of instalments (4, 7, 14, 21, 28, 35, 42 or 
56), with extra conditions needed only when the number of instalments was 4 or 7 in order 
for at least 75% of actual daily-doses to be recovered correctly, see APPENDIX1: actual 
agreement-rate was 88% overall. 
Recovered or actual daily-dose at cohort-entry was available for 26,533 (73%) of clients in 
Scotland’s 2009-2015 cohort, including for 7,349 (58%) of the cohort’s 12,743 CHI-identified 
clients whose prescriber was other-source, see Table 1. Recovered or actual daily-dose was 
available for 19,184 (81%) of 23,604 CHI-identified clients whose prescriber was GP. 
Death-rates for Scotland’s 2009-2015 methadone-prescription cohort; and when restricted 
to 26,533 clients with actual or recovered daily-dose of prescribed methadone. 
Scotland’s 2009-2015 methadone-prescription cohort comprised 36,347 CHI-identified 
methadone-prescription clients who experienced 1,857 non-DRDs and 1,323 DRDs, including 
546 methadone-specific DRDs, in 192,928 person-years (pys) of follow-up, see Table 2.  
Clients’ non-DRD rate was 9.6 per 1000 pys versus their DRD-rate of 6.9 per 1000 pys, both 
precisely-estimated. The 65% of clients with a GP-prescriber had lower DRD-rate (and lower 
methadone-specific DRD-rate) than clients whose prescriber was other-source. Two-thirds 
of clients were male, for whom methadone-specific DRD-rate was lower at 2.6 per 1000 pys 
(95% CI: 2.4-2.9) than for females (3.2, 95% CI: 2.8-3.7).  
Both DRD-rate and methadone-specific DRD rate increased with age-group at cohort-entry, 
the latter more steeply. The modal age-group at accrual to Scotland’s 2009-2015 
methadone-prescription cohort was 25-34 years of age (44% of clients) with only 8% of 
clients aged 15-24 years. Methadone-specific DRD-rate was significantly higher for clients in 
the top quintile for prescribed quantity at accrual to the cohort (qQ5: 4.3 per 1000 pys, 95% 
CI: 3.7-5.0) than for clients in the middle quintile (qQ3: 2.1 per 1000pys, 95% CI: 1.7-2.6). 
Table 3 presents corresponding information for the 26,533 clients with actual or recovered 
daily-dose of prescribed methadone at first CHI-identified prescription, 72% of whom had a 
GP-prescriber. Their DRDs numbered 995, including 420 methadone-specific DRDs. 
Methadone-specific DRD-rate was significantly higher for clients in the top quintile for 
prescribed daily-dose at accrual (dQ5 [> 90 mg]: 5.0 per 1000 pys, 95% CI: 4.2-6.0) than for 
clients in the middle quintile (dQ3 [50-70 mg]: 2.7 per 1000 pys, 95% CI: 2.2-3.3). 
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Adjusted hazard-ratios for methadone-specific DRDs in Scotland’s 2009-2015 methadone-
prescription cohort. 
Baseline quintile for prescribed quantity, Table 4: For methadone-specific DRDs, interaction 
between gender and age-group is unnecessary (chi-square on 3 degrees of freedom of 4.00, 
p ~ 0.026, see APPENDIX2). Females have higher HR (1.4) than males; HRs increase very 
steeply with age-group at cohort-entry, being 3-fold higher for clients 45+ years and 2-fold 
greater for clients aged 35-44 years than if 25-34 years old at cohort-entry. Only the top 
quintile for quantity of prescribed methadone was associated with a significantly increased 
HR compared to qQ3. Clients whose prescription-source was non-GP had significantly higher 
methadone-specific risk (HR, 1.36); likewise, DRD-risk (see APPENDIX2: HR, 1.31). 
Baseline quintile for recovered or actual daily-dose, Table 5:  For methadone-specific DRDs, 
females are disadvantaged (HR 1.3, 95% CI: 1.0-1.6) and the steepness of increase in HRs, 
both age-related and by quintile for baseline daily-dose, is much greater than for all DRDs 
(see APPENDIX2). By age-group at cohort-entry, HR was 3-fold higher (95% CI: 2.4 to 4.2) at 
45+ years than at 25-34 years. For dQ5, HR was also 3-fold higher (95% CI: 2.2 to 4.5) than 
for dQ1 and significantly greater than for dQ3 (HR = 3.15/1.68 or 1.88; 95% CI: 1.13 to 3.12), 
itself significantly greater than dQ1. Finally, higher HR for methadone-specific DRD was 
again associated with other-source prescribers (HR, 1.3, 95% CI: 1.1-1.6). 
Notice that for 420 clients aged 45+ years at cohort-entry who received baseline methadone 
daily-dose greater than 90 mg, methadone-specific DRD-rate was 6.5 per 1000 pys (95% CI: 
3.9 to 10.7, based on 15 methadone-specific DRDs in 2,138 pys,) versus 1.6 (95% CI: 1.1 to 
2.4, based on 24 methadone specific DRDs in 14,869 pys) for 2,627 clients in dQ3 and aged 
25-34 years at cohort-entry. 
Sensitivity analyses: See APPENDIX3 for three sensitivity analyses. The first relates to 
current age-group rather than age-group at cohort-entry (Table A4). Since clients’ age-group 
changes at most once during follow-up, age-effects sharpened only slightly with current 
age-group as alternative to age-group at accrual.  The second focuses on GP-clients only, as 
GPs’ prescriptions were the basis for our recovery-rules (Table A5), but still endorses Table 
5.  Thirdly, APPENDIX3 re-estimates Table 5 for the sub-cohort of mainly prevalent CHI-
identified clients whose cohort-entry was in July to December 2009 (Table A6) versus later-
recruited CHI-identified clients (Table A7). The mainly prevalent sub-cohort is the larger; 
clients are older at cohort-entry, only 19% had a non-GP prescriber and only 5% had 
baseline daily-dose in dQ1. Nonetheless, inferences about age-group and dQs are broadly 
similar for the two sub-cohorts. We note, however, that the mainly prevalent clients’ hazard 
of methadone-specific DRD did not differ by prescription-source. 
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Discussion 
Summary of main findings 
Daily-dose at first CHI-identified methadone prescription was analysed for 73% of clients in 
Scotland’s 2009-2015 methadone-prescription cohort. Daily-doses greater than 50 mg up to 
70 mg comprised the mid-quintile (dQ3). Top quintile (dQ5) was daily-dose >90 mg, within 
which mean daily-dose (sd) was 117 mg (sd 25). 
For methadone-specific DRDs, HR increased steeply for the two older age-groups and 
steadily with quintile for daily-dose through to 3.1 (95% CI: 2.2 to 4.5) for dQ5; and females 
were at greater risk, a new finding.  
For methadone-specific DRDs and for all DRDs, we found an increased hazard (HR 1.3) 
associated non-GP prescribers: clients’ physical and psychiatric comorbidities may be less 
well-known by other-prescribers than by GPs.  
For context, non-DRDs outnumbered DRDs by 3:1 for methadone-prescription clients aged 
45 years and over.  
 
Key considerations 
Notwithstanding the substantial reduction in harms (overdose deaths, criminality and 
blood-borne virus risks) that opioid substitution therapy has delivered for younger heroin 
users, the risk of methadone-specific DRD increases both as clients age into their 40s and 
50s; and steadily with baseline quintile for daily-dose of prescribed methadone. 
Guidelines for methadone-clients recommend a daily-dose of 60-120 mg [27]. Adherence to 
prior guidance was checked by prescribing surveys [28-31] or evidence-synthesis [1]. But 
Scotland’s 2009-2015 methadone-prescription cohort is the first major cohort 
internationally to have analysed the joint effects of gender, age-group and baseline daily-
dose of prescribed methadone on both methadone-specific DRDs and all DRDs.  
In some individuals, females especially [32], methadone (unlike buprenorphine [18]) is 
associated with prolongation of the QTc interval leading to the development of Torsades de 
Pointes and cardiac arrest [33]. Undiagnosed QTc prolongation may manifest as methadone-
specific DRDs.  
Periodic electrocardiograms are recommended for clients receiving more than 100 mg of 
methadone daily [33], but not achieved in practice. Other risk-factors for QTc prolongation 
include co-morbidities such as circulatory or liver disease; co-prescribing for mental or 
physical ill-health [34]; use of both methadone and cocaine; and being female [32, 35].  
Could the latter partly explain our novel finding that females are at higher risk of 
methadone-specific DRD [35-38]? 
Confounding between methadone-specific DRD-risk and the client’s daily-dose of prescribed 
methadone (dQ) cannot be excluded. However, of Hill’s nine criteria for ascribing cause [39], 
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dQs meet at least six: strength of association, specificity (versus all DRDs), temporality, 
biological gradient, plausibility, and coherence.  
Balancing of prescribing risks is challenging in clinical practice, never more so than when 
managing chronic opiate dependency. Risks include [27]: the toxicity of prescribed opiates; 
co-existing respiratory, cardiovascular and metabolic hazards, for example from 
compromised liver capacity; the potential dangers of cumulative doses of multiple drugs 
beyond an individual patient’s current tolerance; compounded by ignorance of the nature, 
strength and pharmacological characteristics of drugs that clients may access on the illegal 
market. The latter vary notoriously in time and place.  
The above considerations produce an environment of high risk for overdose toxicity and 
sudden death. Information, as in this paper, which might mitigate some of these risks is, 
therefore, important. 
We have raised a concern about higher DRD-risks for methadone-clients of non-GP 
prescribers: in particular, for methadone-prescription clients whose cohort entry-date was 
during 2010-2015, a period when non-medical prescribing in the management of substance 
misuse had expanded in Scotland, as elsewhere [40]. Scotland’s GPs have not been reluctant 
to manage methadone-prescriptions for clients with major co-morbidities as around 80% of 
CHI-identified clients whose cohort-entry was July-December 2009 had GP-prescribers. In 
terms of risk-mitigation, it might be helpful for GP Summary Care Records to be routinely 
available to specialist service prescribers so that they are aware of ageing clients’ co-
morbidities. 
In a changing landscape of funding, commissioning of services and basic training of 
prescribers, both Scotland and the rest of the UK are moving towards a wider range of 
prescribers who include pharmacists and specialist nurses. Our paper draws attention to the 
complexity of need that ageing methadone-clients have for interventions from a variety of 
chronic disease specialists (respiratory, cardiovascular and gastrointestinal) beyond their 
immediate drug problems. Primary care, in its widest sense, aspires to be the focus for 
multidisciplinary care. 
 
Strengths and limitations of this study 
First, Scotland has a national protocol for toxicology at forensic autopsies which underwrites 
the opioid-specificity of Scotland’s DRDs. Second, and unparalleled for a national cohort, we 
could analyse quintiles for daily-dose of prescribed methadone at cohort-entry for over 
26,500 methadone-clients in 2009-2015 who experienced 995 DRDs, 420 of them 
methadone-specific DRDs. Thirdly, representativeness in terms of daily-dose at cohort-entry 
is supported because actual or recovered daily-dose was available for 73% of all clients in 
Scotland’s CHI-identified methadone-client cohort; and for 81% of GP-clients.  
Fourth, to minimize ascertainment bias, we considered only the baseline (not time-varying) 
quantity of methadone prescribed at first CHI-identified prescription. This first CHI-identified 
prescription defined the client’s entry to Scotland’s methadone-client cohort (2009-2015) 
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but was not typically the client’s first methadone prescription, especially if cohort-entry was 
in 2009. Accrual-date was July-December 2009 for 57% of clients, indicating that clients 
were mainly prevalent at cohort-entry, see also Gao et al. [5]. Clients whose first CHI-
identified methadone prescription occurred during 2010 to June 2015 include incident 
clients whose baseline daily-dose of methadone was captured during the clients’ titration 
phase. 
Fifth, our results on quantity and daily-dose were robust when restricted to GP-clients only 
or based on current age-group versus age-group at cohort-entry or when the mainly 
prevalent sub-cohort of clients whose cohort-entry was in July to December 2009 was 
analysed separately. 
There are several limitations. First, only 66% of all Scotland’s methadone-prescriptions in 
2009-2015 were CHI-identified. However, as a best estimate, our 36,347 CHI-identified 
methadone-clients represent 80% (plausible range: 70% to 90%) of Scotland’s methadone-
clients during 2009-2015, because a substantial proportion of methadone-prescriptions 
which lack a CHI-number may pertain to already CHI-identified clients. Hence, we do not use 
time-updated quantity prescribed or daily-dose because we cannot be certain that the most 
recent CHI-identified methadone-prescription is the client’s most recent methadone-
prescription. 
In deriving simple rules for recovery of daily-dose, a limitation was that actual daily-doses 
were available electronically from GP-prescriptions only but recovery-rules were applied to 
other-source prescriptions on the reasonable assumption that the same relationships hold. 
As a check, PH analyses using quintiles for daily-dose were repeated for GP-prescribed 
clients only: and inferences were essentially unaltered. 
Record-linkage studies have limited scope for resolving data-queries. We took a harder line 
than previously on exclusion criteria, respectively for prescriptions and clients.  
The need to substitute the later re-imbursement date for missing 1st prescription-date was a 
minor issue. More importantly, we did not know, and so could not analyse, when clients 
exited from methadone-therapy as the date of their last CHI-identified methadone-
prescription does not exclude later non-CHI-identified prescriptions. Hence, once included in 
the cohort, clients have remained in follow-up. 
Confounding between DRD-risk and the client’s daily-dose quintile cannot be ruled out [18]. 
Age over 45 years and prescribed daily-dose greater than 90 mg may be markers for harder-
to-support clients whose opioid dependency is chronic, who have physical co-morbidities, 
notably circulatory and digestive system diseases, or co-prescriptions for mental or physical 
ill-health [8].   
Finally, we did not request that methadone clients’ co-prescriptions [34] for 
benzodiazepines, antiviral medications, mirtazapine, amitriptyline, sertraline or macrolide 
antibiotics (to name but a few) be linked-in because the added time and complexity would 
not have been warranted given that illicit supplies would have remained unaccounted for: 
and constitute most of the benzodiazepines present at Scotland’s DRDs [8]. 
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Conclusions 
Scotland’s 2009-2015 methadone-prescription cohort helps to explain why UK official 
statistics on DRDs and opioid-specific deaths in the second decade of 21st show stark 
increases by age-group, and disproportionately so for females [10].  Methadone-
prescription clients, including CHI-unidentified, during July 2009 to June 2015 accounted for 
around 70% (546/0.80 coverage] of Scotland’s 983 methadone-specific DRDs in July 2009 to 
31 December 2015.  
Our analyses shed an uncompromising light on the wave of age-related, opioid-specific 
DRDs that overwhelms survivors from the UK’s heroin injector epidemics of the early 1980s. 
Clinicians have a difficult balance to strike. Unlike record-linkage studies, official statistics do 
not chart clients’ non-DRDs, which predominate over DRDs by at least 3: 1 as clients age 
beyond 45 years. And sustained methadone maintenance, as recommended [27], has halved 
the DRD-rate that clients would otherwise have experienced at an age when DRDs did 
predominate. 
Urgently, interventions are needed to de-escalate ageing methadone-clients’ risk not only of 
methadone-specific DRD but also of their major causes of non-DRDs [19]. Practitioners must 
balance:  moderation of clients’ daily-dose of methadone, ideally to below 90 mg if clients 
are willing; review of circulatory or digestive co-morbidities which respectively risk sudden 
death masquerading as methadone-specific DRD or prolongation of methadone’s half-life; 
support for smoking cessation to manage better the client’s respiratory and circulatory 
diseases; hepatitis C virus clearance by directly acting antiviral therapy; and review of 
medications prescribed for psychiatric and physical co-morbidities for possible interactions 
with methadone [34].  
Methadone exhibits large inter-individual variation in response, a narrow therapeutic index 
and interacts with a range of other drugs commonly prescribed for ageing methadone-
prescription clients’ co-morbidities. Too little is known about the age-related or gendered 
pharmacogenomics, pharmacokinetics and pharmacodynamics of methadone [22, 32, 41].  
[4,391 words] 
Legend for Figure 1 Exploratory data analysis: from Scotland’s over 2.9 million methadone-
prescriptions during 1 July 2009 to 30 June 2015 to 36,347 CHI-identified methadone-
prescription clients followed-up to 31 December 2015. 
 
Conflicts of Interest: LG has no conflicts; JRR chaired Scotland’s National Forum on Drugs-Related 
Deaths and served on UK’s Independent Expert Working Group on Drug Misuse and Dependence; 
SMB holds GSK shares and served on Scotland’s National Naloxone Advisory Group. 
 
Data Sharing: Data were made available for analysis after our application to Scotland’s Electronic 
Data Research and Innovation Service (eDRIS) was approved by Scotland’s Public Benefit and Privacy 
Panel (PBPP). The data can be accessed by other research-teams who submit a successful PBPP-
application via eDRIS but are not available directly from the authors.  
 
14 
 
References 
1. Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on 
deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and 
Scotland. British Medical Journal 2010; 341:640 (pico) and British Medical Journal 2010; 
341:c4851 (doi:10.1136/bmj.c4851 for 7 pages). 
2. White M, Burton R, Darke S, Eastwood B, Knight J, Millar T, Musto V, Marsden J. Fatal opioid 
poisoning: a counterfactual model to estimate the preventive effects of treatment for opioid use 
disorder in England. Addiction 2015; 110: 1321–1329. 
3. Merrall ELC, Bird SM, Hutchinson SJ. Mortality of those who attended drug services in Scotland 
1996-2006: record linkage study. International Journal of Drug Policy 2012; 23: 24 - 32. 
4. Pierce M, Hayhurst K, Bird SM, Hickman M, Seddon T, Dunn G, Millar T. Quantifying crime 
associated with drug use among a large cohort of sanctioned offenders in England and Wales. 
Drug and Alcohol Dependence 2015; 155: 52-59. See also  
http://dx.doi.org/10.1016/j.drugalcdep.2015.08.018. 
5. Gao L, Dimitropoulou P, Robertson JR, McTaggart S, Bennie M, Bird SM. Risk-factors for 
methadone-specific deaths in Scotland’s methadone-prescription clients between 2009 and 
2013. Drug and Alcohol Dependence 2016; 167: 214-223. 
6. Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ. Prevalence of Hepatitis C 
carriage in Scottish prisons: Willing Anonymous Salivary Hepatitis C surveillance linked to self-
reported risks. Quarterly Journal of Medicine 1999; 92: 25 - 32. 
7. McDonald SA, Hutchinson SJ, Mills PR, Bird SM, Robertson C, Dillon JF, Springbett A, Goldberg 
DJ.Diagnosis of hepatitis C virus infection in Scotland’s injecting drug user population. 
Epidemiology and Infection 2010; 138: 393 – 402. 
8. Barnsdale L, Gounari X, Graham L. The National Drug-related deaths Database (Scotland) report: 
analysis of deaths occurring in 2015 and 2016. Information Services Division Scotland: Edinburgh 
2018; 12 June. See http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/2018-
06-12/2018-06-12-NDRDD-Report.pdf (last accessed 13 December 2018). Also two preceding 
annual reports. 
9. McDonald S, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Dillon JF, Goldberg DJ. 
Hospitalisation for an alcohol-related cause among injecting drug users in Scotland: increased 
risk following diagnosis with hepatitis C infection. International Journal of Drug Policy 2011; 22: 
63 - 69.  
10. National Records of Scotland. Drug-related deaths in Scotland in 2018. Natl. Rec. Scotl. July 2019  
https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-
events/deaths/drug-related-deaths-in-scotland/2018; last accessed 19.07.2019.  
11. Bird SM, Hutchinson SJ, Goldberg DJ. Drug-related deaths by region, gender and age-group per 
100 injectors: Scotland, 2000 - 2001. Lancet 2003; 362: 941 - 944. 
12. King R, Bird SM, Hay G, Hutchinson SJ. Updated estimation of the prevalence of injecting drug-
users in Scotland via capture-recapture methods. Statistical Methods in Medical Research 2009; 
18: 341 – 359. 
13. King R, Bird SM, Overstall A, Hay G, Hutchinson SJ. Estimating prevalence of injecting drug users 
and associated heroin-related death-rates in England using regional data and incorporating prior 
information. Journal of the Royal Statistical, Series A 2014; 177: 1 – 28. 
14. Pierce M, Bird SM, Hickman M, Millar T. National record-linkage study of mortality for a large 
cohort of opiate users ascertained by drug treatment or criminal justice sources, 2005-2009.  
Drug and Alcohol Dependence 2015; 146: 17-23.  
15. Larney S, Hickman M, Fiellin DA, Dobbins T, Nielson S, Jones NR, Mattick RP, All R, Degenhardt L. 
Using routinely collected data to understand and predict adverse outcomes in opioid agonist 
 
15 
 
treatment: protocol for the Opioid Agonist Treatment Safety (OATS) Study. BMJ Open 2018; 8 
(8): http://dx.doi.org/10.1136/bmjopen-2018-025204. 
16. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among 
regular or dependent users of heroin or other opioids: a systematic review and meta-analysis of 
cohort studies. Addiction 2011; 106: 32-51. 
17. Pierce M, Millar T, Robertson JR, Bird SM. Ageing opioid users’ increased risk of methadone-
specific death in the UK. International Journal of Drug Policy 2018: 55; 121 – 127. 
18. Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Strang J, Telfer M, Vickerman P, Macleod J, 
Millar T. The impact of buprenorphine and methadone on mortality : a primary care cohort study 
in the United Kingdom. Addiction 2018; 113: 1461 – 1476. See 
https://doi.org/10.1111/add.14188 
19. Gao L, Robertson JR, Bird SM. Non-drug related and opioid-specific causes of 3262 deaths in 
Scotland’s methadone-prescription clients, 2009-2015. Drug and Alcohol Dependence 2019; 197: 
262-270. 
20. Bell J. Pharmacological maintenance treatments of opiate addiction. British Journal of 
Pharmacology 2012; 77: 253 – 263. 
21. Mouly S, Bloch V, Peoc’h K, Houze P, Labat L, Ksouda K, Simomeau G, Decleves X, bergmann JF, 
Scherrmann J-M, Laplanche J-L, Lepine J-P, Vorspan F. Methadone dose in heroin-dependent 
patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. 
British Journal of Clinical Pharmacology 2014; 79: 967 – 977. 
22. Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, Babu MA. 
Pharmacogenomics of GPCR drug targets. Cell 2018; 172: 1 – 14. 
23. National Records of Scotland. Drug-related deaths in Scotland in 2016. Natl. Rec. Scotl. 2017 URL 
https://www.nrscotland.gov.uk/files//statistics/drug-related-deaths/drd2016/drug-related-
deaths-16-pub.pdf; last accessed 02.05.2018.  
24. Pavis S, Morris AD. Unleashing the power of administrative health data: the Scottish model. 
Public Health Research Practice 2015; 25: e2541541. doi: 
10.17061/phrp2541541.25.https://doi.org/http://dx10.17061/phrp2541541 
25. Alvarez-Madrazo S., McTaggart S, Nangle C, Nicholson E, Bennie, M. Data Resource Profile: The 
Scottish National Prescribing Information System (PIS). International  Journal of Epidemiology 
2016;  45: 714–715. See https://doi.org/10.1093/ije/dyw060. 
26. McTaggart S, Nangle C, Caldwell J, Alvarez-Madrazo S, Colhoun H, Bennie M. Use of text-mining 
methods to improve efficiency in the calculation of drug exposure to support 
pharmacoepidemiology studies. International Journal of Epidemiology 2018; 47: 617 – 624. 
27. Independent Expert Working Group on Drug Misuse and Dependence (chairman: Professor Sir 
John Strang). Clinical Guidelines on Drug Misuse and Dependence, Update 2017. 
(http://dx.doi.org/10.1016/j.drugpo.2010.04.003).  
28. Strang J, Sheridan J, Barber N. Prescribing injectable and oral methadone to opiate addicts. 
Results from the 1995 national postal survey of community pharmacies in England and Wales. 
British Medical Journal 1996; 313: 270 – 272. 
29. Strang J, Sheridan J. National and regional characteristics of methadone prescribing in England 
and Wales: local analyses from the 1995 national survey of community pharmacies. Journal of 
Substance Misuse 1998; 3: 240 – 246. 
30. Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and 
other opioids to addicts: national survey of GPs in England and Wales. British Journal of General 
Practice 2005; June: 444 – 451. 
31. Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction 
change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts 
by general practitioners and hospital doctors in England, 1995-2005. Addiction 2007; 102: 761 – 
 
16 
 
770. 
32. Graziani M, Nistica R. Gender differences in pharmacokinetics and pharmaco-dynamics of 
methadone substitution therapy. Frontiers in Pharmacology 2015; 6: 122. 
33. Medicines and Healthcare products Regulatory Agency. Risk of QT interval prolongation with 
methadone. Current Problems in Pharmacovigilance 2006; 31: 6. 
34. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among opioids, 
methadone and buprenorphine, and other frequently prescribed medications: a review. 
American Journal on Addictions 2009; 19: 4 – 16. 
35. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor 
for torsades de pointes associated with cardiovascular drugs. Journal of the American Medical 
Association 1993; 270: 2590 – 2597. 
36. Kest B, Sarton E, Dahan A. Gender differences in opioid-mediated analgesia. Anesthesiology 
2000; 93: 539 – 547. 
37. Lee C W-S, Ho, I-K. Sex differences in opioid analgesia and addiction: interactions among opioid 
receptors and oestrogen receptors. Molecular Pain 2013; 9: 45 – 54. 
38. Bawor M, Dennis BB, Anglin R, Steiner M, Thabane L, Samaan Z. Sex differences in outcomes of 
methadone maintenance treatment for opioid addiction: a systematic review protocol. 
Systematic Reviews 2014; 3: 45. 
39. Hill AB. The environment and disease: association or causation? Proceedings of the Royal 
Society of Medicine 1965; 58: 295-300. 
40. Public Health England. Non-medical prescribing in the management of substance misuse. Public 
Health England, London: July 2014. See https://www.gov.uk/government/publications/non-
medical-prescribing-in-the-management-of-substance-misuse (last accessed: 15 February 2020). 
41. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. Journal of Pain & Palliative 
Care Pharmacotherapy 2005; 19: 13-24. 
 
Funding: Medical Research Council MRC Biostatistics Unit. The funder did not influence 
where, when or what to publish. 
 
Contributions: Study-concept by Bird and Robertson; recovery-rules by Gao and Bird; 
statistical analyses by Gao and Bird; background, discussion and referencing by Robertson 
and Bird; critique and finalization of manuscript by all authors.  
 
17 
 
Table 1: Descriptive statistics for Scotland’s 2009-2015 CHI-identified methadone-
prescription cohort 
Descriptor 2009-2015 CHI-identified methadone-prescription cohort 
All clients With actual or recovered daily-dose 
at first CHI-identified prescription 
Clients 36,347 26, 533 
Person-years (pys) 192,928 pys 144,697 pys 
Deaths    3,180   2,342 
DRDs (%)     1,323 (42%)      995 (42%) 
Methadone-specific 
DRDs (% of all DRDs) 
       546 (41%)      420 (42%) 
Heroin-specific DRDs  
(% of all DRDs) 
       320 (24%)      241 (24%) 
Heroin + methadone 
DRDs (% of all DRDs) 
       309 (23%)      219 (22%) 
Gender 
Females (%) 12,096 (33%)   8,744 (33%) 
Males (%) 24,251 (67%) 17,789 (67%) 
Prescription source 
GP-prescriber 23,604 (65%) 19,184 (72%) 
Other-source prescriber 12,743 (35%)   7,349 (28%) 
Means (sd) 
Age at accrual  34.8 years ( 7.9) 34.9 years (  7.8) 
1st actual or recovered 
daily-dose at accrual  
61.7 mg    (34.2) 
11,055 clients with actual 
daily-dose 
62.8 mg     (33.2)  
26,533 clients with actual or 
recovered daily-dose 
Quantity methadone at 
1st CHI-identified script in 
accrual month 
1,181 mg (1,116) 1,260  mg (1,112) 
Client’s number of CHI-identified prescriptions with actual or recovered daily-dose in accrual 
month 
1  17,349 (65%) 
2   6,393 (24%) 
3   1,926 (  7%) 
4       601 ( 2%) 
5 or more       264 ( 1%) 
Clients’ accrual era 
July-December 2009 20,728 16,350 
2010 6,489 4,428 
2011 2,993 1,973 
2012 1,938 1,274 
January-June 2013 813 517 
July-December 2013 985 577 
2014 1,661 979 
January-June 2015 740 435 
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Table 2: Death-rates (95% confidence interval) for 1000 person-years for all 36,347 clients in 
Scotland’s 2009-2015 CHI-identified methadone-prescription cohort 
All CHI-identified methadone-prescription clients 
Covariate Clients 
(%) 
Total 
CHI-
identified 
prescriptions 
Person-
years 
Non-
DRDs 
 
DRDs  
 
 
Methadone
-specific 
DRDs [M]  
(%) 
Heroin-
specific 
DRDs 
[H] 
M+H 
DRDs 
Scotland-
wide 
36,347 1,931,062 192,928 1,857 1,323 
 
546   320 309 
Death-rates (95% confidence interval) 9.6 
(  9.2-10.1) 
  6.9 
(6.5-7.2) 
  2.8 
(2.6-3.1) 
     1.7 
(1.5-1.9) 
  1.6 
(1.4-1.8) 
Prescription-source 
GP 23,604 
(65%)  
1,419,112 130,856 1,351 
(73%) 
846 
(64%) 
347 
(64%) 
  226   165 
Death-rates (95% confidence interval) 10.3 
(  9.8-10.9) 
  6.5 
(6.0-6.9) 
  2.7 
(2.4-2.9) 
  
Other -
source 
12,743 
(35%) 
511,950   62,072    506 
(27%) 
477 
(36%) 
199 
(36%) 
    94  144 
Death-rates (95% confidence interval)   8.2 
( 7.5-  8.9) 
  7.7 
(7.0-8.4) 
  3.2 
(2.8-3.7) 
  
Gender 
Male 24,251 
(67%) 
1,253,996 128,042 1,315 
(71%) 
908 
(69%) 
  339 
(62%) 
  252  218 
Death-rates (95% confidence interval) 10.3 
(  9.7-10.8) 
  7.1 
(6.6-7.6) 
  2.6 
(2.4-2.9) 
  
Female 12,096 
(33%) 
677,066   64,886 542 
(29%) 
415 
(31%) 
  207 
(38%) 
    68    91 
Death-rates (95% confidence interval)   8.4 
(  7.7-  9.1) 
  6.4 
(5.8-7.0) 
  3.2 
(2.8-3.7) 
  
Age-group at baseline, that is: at accrual 
15-24 
years 
2,965 
 (  8%) 
131,287   14,941    50 
( 3%) 
  64 
(  5%) 
    20 
(  4%) 
     23     15 
Death-rates (95% confidence interval)   3.3 
( 2.5-   4.4) 
  4.3 
(3.4-  5.5) 
  1.3 
(0.9-2.1) 
  
25-34 
years 
15,957 
(44%) 
862,064   86,825   408 
(21%) 
504 
(38%) 
  163 
(30%) 
  154  137 
Death-rates (95% confidence interval)   4.7 
( 4.3-   5.2) 
  5.8 
(5.3-  6.3) 
  1.9 
(1.6-2.2) 
  
35-44 
years 
13,416 
(37%) 
751,673   72,207   803 
(42%) 
567 
(43%) 
  264 
(48%) 
  116   118 
Death-rates (95% confidence interval)   11.1 
(10.4-11.9) 
  7.9 
(7.2-  8.5) 
  3.7 
(3.2-4.1) 
  
45 + 
Years 
  4,009 
(11%) 
186,038   18,956   596 
(34%) 
188 
(14%) 
  99 
(18%) 
    27     39 
Death-rates (95% confidence interval) 31.4 
(29.0-34.1) 
  9.9 
(8.6-11.4) 
  5.2 
(4.3-6.4) 
  
Quintiles for baseline quantity of prescribed methadone defined by 1st CHI-identified 
prescription1  
qQ1:   5 to 
270  mg 
 7,282 
(20%) 
321,751   32,396    368 
(20%) 
224 
(17%) 
  77 
(14%) 
75 41 
Death-rates (95% confidence interval) 11.4 
(10.3-12.6) 
6.9 
(6.1-7.9) 
2.4 
(1.9-3.0) 
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qQ2:  271 
to   645 mg 
 7,259 
(20%) 
378,255   37,117    384 
(21%) 
271 
(20%) 
  92 
(17%) 
77 68 
Death-rates (95% confidence interval) 10.3 
( 9.4-11.4) 
7.3 
(6.5-8.2) 
2.5 
(2.0-3.0) 
  
qQ3:  646 
to 1120 mg 
7,298 
(20%) 
438,174   40,542 351 
(19%) 
250 
(19%) 
  85 
(16%) 
71 66 
Death-rates (95% confidence interval) 8.7 
( 7.8- 9.6) 
6.2 
(5.4-7.0) 
2.1 
(1.7-2.6) 
  
qQ4: 1121 
to 1960 mg 
7,915 
(22%) 
450,504   44,478 413 
(22%) 
288 
(22%) 
128 
(23%) 
62 69 
Death-rates (95% confidence interval) 9.3 
( 8.4-10.2) 
6.5 
(5.8-7.3) 
2.9 
(2.4-3.4) 
  
qQ5: > 
1960 mg 
6,593 
(18%) 
351,378   38,395 341 
(18%) 
290 
(22%) 
164 
(30%) 
35 65 
Death-rates (95% confidence interval) 8.9 
( 8.0- 9.9) 
7.6 
(6.7-8.5) 
4.3 
(3.7-5.0) 
  
1Quintiles for baseline quantity of prescribed methadone defined by 1st CHI-identified prescription, 
are as follows qQ1:   5 to 270 mg; qQ2:  271 to   645 mg; qQ3:  646 to 1120 mg; qQ4: 1121 to 1960 mg;    
qQ5: > 1960 mg 
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Table 3: Death-rates (95% confidence interval) for 1000 person-years for 26,533 clients in 
Scotland’s 2009-2015 CHI-identified methadone-prescription cohort with actual or 
recovered daily-dose at first CHI-identified prescription 
Clients with actual or recovered daily-dose at first CHI-identified prescription 
Covariate Clients 
(%) 
Total CHI-
identified 
prescriptions 
Person-
years 
Non-
DRDs 
(%) 
DRDs 
 
(%) 
Methadone
-specific 
DRD [M] 
(%) 
Heroin-
specific 
DRD 
[H] 
M+H 
DRDs 
Scotland-
wide 
26,533 1,510,417 144,697  1,347 
 
995 420   241 219 
Death-rates (95% confidence interval) 9.3 
(8.8-9.8) 
  6.9 
(6.5-7.3) 
  2.9 
(2.6-3.2) 
  
Prescription-source 
GP 19,184
(72%) 
1,178,699 107,248 1,030 
(76%) 
706 
(71%) 
  293 
(70%) 
  184   136 
Death-rates (95% confidence interval) 9.6 
(9.0-10.2) 
  6.6 
(6.1-7.1) 
  2.7 
(2.4-3.1) 
  
Other -
source 
 7,349 
(28%) 
   331,718   37,449 317 
(24%) 
289 
(29%) 
  127 
(30%) 
  57   83 
Death-rates (95% confidence interval)   8.5 
( 7.6-9.5) 
  7.7 
(6.9-8.7) 
  3.4 
(2.9-4.0) 
  
Gender 
Male 17,789
(67%) 
   985,116   96,377 970 
(72%) 
696 
(70%) 
 269 
(64%) 
  196   156 
Death-rates (95% confidence interval) 10.1 
(9.5-10.7) 
  7.2 
(6.7-7.8) 
  2.8 
(2.5-3.2) 
  
Female   8,744 
(33%) 
   525,301   48,320 377 
(28%) 
299 
(30%) 
151 
(36%) 
   45   63 
Death-rates (95% confidence interval) 7.8 
( 7.0-8.6) 
  6.2 
(5.5-6.9) 
  3.1 
(2.7-3.7) 
  
Age-group at baseline, that is: at accrual  
15-24 
years 
  1,991 
 (  8%) 
     96,353   10,355    36 
( 3%) 
  40 
(  4%) 
   13 
(  3%) 
    14     8 
Death-rates (95% confidence interval)   3.5 
( 2.5-  4.8) 
  3.9 
(2.8-5.3) 
  1.3 
(0.7-2.2) 
  
25-34 
years 
11,567 
(44%) 
   666,980   64,492   299 
(22%) 
370 
(37%) 
  123 
(29%) 
  115   93 
Death-rates (95% confidence interval)   4.6 
( 4.1-  5.2) 
  5.7 
(5.2-6.4) 
  1.9 
(1.6-2.3) 
  
35-44 
years 
10,054 
(38%) 
   599,478   55,553  594 
(44%) 
435 
(44%) 
  206 
(49%) 
  91  88 
Death-rates (95% confidence interval)   10.7 
( 9.9-11.6) 
  7.8 
(7.1- 8.6) 
  3.7 
(3.2-4.3) 
  
45 + 
Years 
  2,921 
(11%) 
    147,606   14,297 418 
(31%) 
150 
(15%) 
   78 
(19%) 
  21   30 
Death-rates (95% confidence interval) 29.2 
(26.6-32.2) 
10.4 
(8.9-12.3) 
  5.4 
(4.4-6.8) 
  
Quintiles (qQ) for baseline quantity of prescribed methadone defined by 1st CHI-identified 
prescription1  
qQ1:   5 to 
336 mg 
 5,318 
(20%) 
251,575   25,025 274 
(20%) 
179 
(18%) 
 57 
(14%) 
64 29 
Death-rates (95% confidence interval) 11.0 7.2 2.3   
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(9.9-12.3) (6.2-8.3) (1.8-3.0) 
qQ2:  337 
to   765 mg 
5,296 
(20%) 
308,169   28,345 268 
(20%) 
207 
(21%) 
 66 
(16%) 
65 53 
Death-rates (95% confidence interval) 9.5 
(8.4-10.7) 
7.3 
(6.4-8.4) 
2.3 
(1.8-3.0) 
  
qQ3: 766 
to 1260 mg 
5,714 
(22%) 
368,734   32,505  291 
(22%) 
191 
(19%) 
  82 
(20%) 
48 38 
Death-rates (95% confidence interval) 9.0 
(8.0-10.0) 
5.9 
(5.1-6.8) 
2.5 
(2.0-3.1) 
  
qQ4: 1261 
to 1960 mg 
4,979 
(19%) 
290,517   28,258 250 
(19%) 
182 
(18%) 
  80 
(19%) 
35 50 
Death-rates (95% confidence interval) 8.9 
(7.8-10.0) 
6.4 
(5.6-7.4) 
2.8 
(2.3-3.5) 
  
Q5: > 1960 
mg 
5,226 
(20%) 
291,422   30,564 264 
(20%) 
236 
(24%) 
135 
(32%) 
29 49 
Death-rates (95% confidence interval) 8.6 
(7.7-9.7) 
7.7 
(6.8-8.8) 
4.4 
(3.7-5.2) 
  
Quintiles (dQ) for baseline daily-dose of prescribed methadone defined by 1st CHI-identified 
prescription2 
dQ1:    
[1 - 34.5] mg 
 5,307 
(20%) 
    244,273   26,499 327 
(24%) 
152 
(15%) 
  41 
(10%) 
54 29 
Death-rates (95% confidence interval) 12.3 
(11.1-13.8) 
5.7 
(4.9-6.7) 
1.6 
(1.1-2.1) 
  
dQ2:  
(34.5-50]mg 
 6,287 
(24%) 
    336,090   32,918 294 
(22%) 
212 
(22%) 
  72 
(17%) 
62 45 
Death-rates (95% confidence interval) 8.3 
(7.4-9.4) 
6.3 
(5.5-7.3) 
2.2 
(1.7-2.8) 
  
dQ3:   
(50 - 70] mg 
 5,892 
(22%) 
    348,984   32,859  274 
(20%) 
208 
(21%) 
  87 
(21%) 
52 55 
Death-rates (95% confidence interval) 8.3 
(7.4-9.4) 
6.3 
(5.5-7.3) 
2.7 
(2.2-3.3) 
  
dQ4:  
(70 - 90] mg 
 4,645 
(18%) 
    288,961   26,658 234 
(17%) 
199 
(20%) 
  91 
(22%) 
44 46 
Death-rates (95% confidence interval) 8.8 
(7.7-10.0) 
7.5 
(6.5-8.6) 
3.4 
(2.8-4.2) 
  
dQ5: > 90 
mg 
 4,402 
(17%) 
    292,109   25,763 218 
(16%) 
224 
(23%) 
129 
(31%) 
29 44 
Death-rates (95% confidence interval) 8.5 
(7.4-9.7) 
8.7 
(7.6-9.9) 
5.0 
(4.2-6.0) 
  
1Quintiles (qQ) for baseline quantity of prescribed methadone defined by 1st CHI-identified 
prescription are as follows qQ1:   5 to 336 mg; qQ2:  337 to   765 mg; qQ3: 766 to 1260 mg; qQ4: 1261 to 1960 mg;  
Q5: > 1960 mg 
2Quintiles (dQ) for baseline daily-dose of prescribed methadone defined by 1st CHI-identified 
prescription are as follows dQ1:   [1 - 34.5] mg;  dQ2:  (34.5-50] mg; dQ3:  (50 - 70] mg;  dQ4: (70 - 90] mg;             
dQ5: > 90 mg 
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Table 4:  Proportional hazards regression for methadone-specific DRDs for 36,347 clients 
with 192,928 person-years of follow-up in Scotland’s 2009-2015 CHI-identified methadone-
prescription cohort, incorporating quintiles for quantity of methadone prescribed at first 
CHI-identified methadone-prescription (qQ). 
 
Quintiles for baseline quantity of prescribed methadone at 1st CHI-identified prescription (qQ) 
qQ regression chi-square of 33.40 on 4 degrees of freedom; p < 0.00001 
 
 
Events 
 
546 Methadone-specific DRDs 
 
Covariates Hazard Ratio (HR) 95% Confidence Interval for HR;  p-value versus baseline 
Prescription-source (baseline: GP-prescriber) 
Other-source 1.36 1.14-1.62;    p ~ 0.001 
Gender (baseline: male) 
Female 1.37 1.15-1.63;    p < 0.001 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.67 0.42-1.07 
25-34  1.00 Baseline 
35-44 2.02 1.66-2.46;    p < 0.001 
45+ years 2.94 2.29-3.78;    p < 0.001 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
qQ1:       5 -   270 mg 1.00 Baseline 
qQ2:   271 -   645 mg    0.98 0.72-1.33 
qQ3    646 - 1120 mg 0.79 0.58-1.07 
qQ4: 1121 - 1960 mg  1.08 0.81-1.44 
qQ5:        > 1960 mg    1.61 1.22-2.11; p ~ 0.001 
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Table 5:  Proportional hazards regression for methadone-specific DRDs for 26,533 clients 
Scotland’s 2009-2015 CHI-identified methadone-prescription cohort with actual or 
recovered daily-dose of methadone at first CHI-identified methadone-prescription and 
144,697 person-years of follow-up. 
Quintiles for actual or recovered daily-dose of methadone at 1st CHI-identified prescription (dQ) 
dQ regression chi-square of 58.99 on 4 degrees of freedom; p < 0.00001 
 
Events 420 Methadone-specific DRDs 
Covariates Hazard Ratio (HR) 95% confidence interval for HR; p-value versus baseline 
Prescription-source (baseline: GP-prescriber) 
Other-source 1.32 1.07-1.63;     p ~ 0.009 
Gender (baseline: male) 
Female 1.29 1.05-1.58;     p ~ 0.013 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.67 0.38-1.19 
25-34  1.00 Baseline 
35-44 2.00 1.60-2.50; p < 0.001 
45+ years 3.15 2.37-4.19; p < 0.001 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
dQ1:   [1 -   34.5]    mg 1.00 Baseline 
dQ2:   (34.5 -   50] mg    1.39 0.95-2.04 
dQ3    (50    -   70] mg 1.68 1.15-2.43; p ~ 0.007 
dQ4:   (70    -   90] mg  2.16 1.49-3.13; p < 0.001 
dQ5:        > 90 mg    3.15 2.21-4.48; p < 0.001 
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APPENDICES 
Appendix1:  Rules for recovery of daily-dose 
Accepted rules for recovery of daily-dose: The performance of recovery rules, see Table A1, 
was tested in alternative settings:  
i) Scotland’s 2013-15 derivation sub-cohort, as defined in Methods: all CHI-
identified prescriptions with daily-dose in clients’ accrual month. 
ii) Scotland’s 2009-2015 methadone-prescription-client cohort: all CHI-identified 
prescriptions with daily-dose in clients’ cohort-entry month. 
As shown in Table A1, recovery rules were generally of the form “quantity divided by D(i)” 
where the value, D (i), depended on the number (i) of instalments, with extra conditions 
needed only when the number of instalments was 4 or 7.  
To be accepted, a recovery-rule for i instalments had to match 75% of actual daily-doses 
issued in i instalments in the accrual month for clients in the derivation sub-cohort. The 
accepted rules recovered 90% of 7,964 relevant daily-doses for clients in the derivation sub-
cohort; and 88% of 8,389 relevant daily-doses in the cohort-entry month for Scotland’s 
2009-2015 methadone-prescription-client cohort. Recovery-rate dropped below 75% in 
Scotland’s 2009-2015 cohort only twice: for 4 instalments (71%) and 35 instalments (67%). 
 
Table A1: Performance of accepted recovery rules for daily-dose 
Number of 
instalments 
with 
acceptable 
recovery-
rule 
Accepted recovery 
rule for daily-dose 
Performance of per-
instalment recovery rule 
Scotland’s   
2009-2015 
methadone-
prescription 
cohort:  
accrual month 
2013-2015 
derivation   
sub-cohort:  
 
accrual month 
  4 If number of 
instalments is the 
same for every 
prescription in 
client’s accrual 
month: divide 
quantity by 28. 
Otherwise divide 
quantity by 4 unless 
answer exceeds 200 
mg, in which case 
divide by 28 
% correct versus actual 
daily-dose 
71% 
(1,251/1,765) 
76% 
(1,374/1,805) 
Increase in daily-dose by 
applying rule 
Increased from 
1,765 to 5,276 
Increased from 
1,805 to 4,413  
Number other-source 
prescriptions with daily-
dose by applying rule 
1,305 1,498  
  7 Divide quantity by 7 
unless answer 
% correct versus actual 
daily-dose 
90% 
(1,818/2,020) 
92% 
(1,289/1,402) 
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exceeds 200 mg, in 
which case divide by 
49, that is: 7 * 7. 
Increase in daily-dose by 
applying rule 
Increased from 
2,020 to 7,550 
Increased from 
1,402 to 4,346 
Number other-source 
prescriptions with daily-
dose by applying rule 
1274   828 
14 Divide quantity by 14 % correct versus actual 
daily-dose 
94% 
(1,950/2,081) 
95% 
(1,710/1,802) 
Increase in daily-dose by 
applying rule 
Increased from 
2,081 to 9,416 
Increased from 
1,802 to 8,229 
Number other-source 
prescriptions with daily-
dose by applying rule 
3,979  3,921  
21 Divide quantity by 21 % correct versus actual 
daily-dose 
86%                     
(  331/  386) 
90%                      
(  353/  391) 
Increase in daily-dose by 
applying rule 
Increased from 
386 to 1,231 
Increased from   
391 to 1,072 
Number other-source 
prescriptions with daily-
dose by applying rule 
135  132 
28 Divide quantity by 28 % correct versus actual 
daily-dose 
96% 
(1,863/1,950) 
97% 
(2,289/2,365) 
Increase in daily-dose by 
applying rule 
Increased from 
1,950 to 6,461 
Increased from 
2,365 to 6,924 
Number other-source 
prescriptions with daily-
dose by applying rule 
2730  2893 
35 Divide quantity by 35 % correct versus actual 
daily-dose 
67%                      
(   24/   36) 
78%                    
(  21/   27) 
Increase in daily-dose by 
applying rule 
Increased from 
36 to 65 
Increased from 
27 to 53         
Number other-source 
prescriptions with daily-
dose by applying rule 
        5      0 
42 Divide quantity by 42 % correct versus actual 
daily-dose 
78%                     
(   59/   76) 
87%                    
(   72/   83) 
Increase in daily-dose by 
applying rule 
Increased from 
76 to 118 
Increased from 
83 to 91 
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Number other-source 
prescriptions with daily-
dose by applying rule 
       5 0 
56 Divide quantity by 56 % correct versus actual 
daily-dose 
96%                      
(   72/   75) 
98%                    
(   87/   89) 
Increase in daily-dose by 
applying rule 
Increased from 
75 to 112 
Increased from 
89 to 109 
Number other-source 
prescriptions with daily-
dose by applying rule 
      11     7  
 
By applying the above eight accepted 
rules for recovery of daily-dose when 
number of instalments is: 
4, 7, 14, 21, 28, 35, 42 or 56 
% correct versus actual 
daily-dose 
88% 
(7,368/8,389) 
90% 
(7,195/7,964) 
 Increase in daily-dose by applying rule Increased from 
8,389 to 30,229 
Increased from 
7,964 to 25,237 
Number other-source prescriptions 
with daily-dose by applying rule 
9,444  9,279  
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Appendix2: Proportional hazards (PH) analysis for all DRDs 
Baseline quintile for prescribed quantity:  For all DRDs, Table A2 shows that the interaction 
between gender and age-group at accrual is highly statistically significant (p ~ 0.0026) and 
signals that female clients’ reduced DRD-hazard (overall HR, 0.82) is reversed for older 
clients. Male clients’ DRD-risk increases with age, being significantly greater for males aged 
45+ years at accrual (HR, 1.59) than if aged 25-34 years; and greater also than for males 
aged 35-44 years (HR = 1.59/1.25 or 1.27, 95% CI: 0.99 to 1.63). There is some indication 
that clients in qQ3 or qQ4 at accrual have reduced DRD-hazard (HR ~ 0.8) compared to qQ1. 
Clients whose prescription-source was non-GP had significantly higher DRD-risk (HR, 1.31). 
For methadone-specific DRDs, interaction between gender and age-group is unnecessary; 
females have higher HR (1.4) than males; HRs increase very steeply with age-group at 
accrual, being 3-fold higher for clients 45+ years at accrual and 2-fold greater for clients 
aged 35-44 years than if 25-34 years old at accrual. Only the top quintile for quantity of 
prescribed methadone was associated with a significantly increased HR compared to qQ3. 
Baseline quintile for recovered or actual daily-dose:  For all DRDs, the significant gender by 
age-group interaction in Table A3 confirms that females enjoy an importantly reduced DRD-
risk under 35 years of age compared to males but, thereafter, the female advantage is 
neutralized. Males’ DRD-risk increases significantly at 35+ years. The HR associated with 
dQ5, top quintile for daily-dose at first CHI-identified prescription, was significantly greater 
than for dQ3 (HR = 1.43/1.06 or 1.35; 95% CI: 1.00 to 1.81). Higher DRD-risk was associated 
with clients whose prescriber was other-source. 
For methadone-specific DRDs, females are disadvantaged (HR 1.3, 95% CI: 1.0-1.6) and the 
steepness of increase in HRs, both age-related and by quintile for 1st daily-dose, is much 
greater than for all DRDs. By age-group, HR was 3-fold higher (95% CI: 2.4 to 4.2) at 45+ 
years of age than at 25-34 years. For dQ5, HR was also 3-fold higher (95% CI: 2.2 to 4.5) than 
for dQ1 and significantly greater than for dQ3 (HR = 3.15/1.68 or 1.88; 95% CI: 1.13 to 3.12), 
itself significantly greater than dQ1. Finally, higher HR for methadone-specific DRD was 
associated with other-source prescribers. 
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Table A2 Proportional hazards regressions for Scotland’s 2009-2015 CHI-identified 
methadone-prescription cohort of 36,347 clients and 192,928 pys, incorporating quintiles 
for quantity of methadone prescribed at first CHI-identified methadone-prescription. 
Quintiles for baseline quantity of prescribed methadone at 1st CHI-identified prescription 
Events 
 
1,323 DRDs 546 Methadone-specific DRDs 
Covariates Hazard ratio (HR) 
95% CI for HR; p-value 
versus baseline 
Hazard 
ratio (HR) 
95% CI for HR; p-value 
versus baseline 
qQ regression, 4df Chi-square 11.87; p ~ 0.018 Chi-square 33.40; p < 0.00001 
Prescription-source (baseline: GP-prescriber) 
Other-source 1.31 1.17-1.47; p < 0.001 1.36 1.14-1.62; p ~ 0.001 
Gender (baseline: male) 
Female 0.95 0.85-1.07 1.37 1.15-1.63; p < 0.001 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.72 0.56-0.94; p ~ 0.015 0.67 0.42-1.07 
25-34  1.00  1.00  
35-44 1.38 1.23-1.56; p< 0.001 2.02 1.66-2.46; p < 0.001 
45+ years 1.79 1.51-2.12; p <0.001 2.94 2.29-3.78; p < 0.001 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
qQ1:       5 -   270 mg 1.00  1.00  
qQ2:   271 -   645 mg    0.99 0.83-1.19 0.98 0.72-1.33 
qQ3    646 - 1120 mg 0.80 0.67-0.96; p ~ 0.015 0.79 0.58-1.07 
qQ4: 1121 - 1960 mg  0.83 0.70-0.99; p ~ 0.040 1.08 0.81-1.44 
qQ5:        > 1960 mg    0.97 0.81-1.15 1.61 1.22-2.11; p ~ 0.001 
Now including interaction for gender by age-group at accrual on 3 degrees of freedom (df) 
Interaction 
regression  
chi-squared on 3df 
 
14.27; p ~ 0.0026 
 
4.00; p ~ 0.26 
Prescription-source (baseline: GP-prescriber) 
Other 1.31 1.17-1.47; p < 0.001 1.36 1.14-1.62; p ~ 0.001 
Gender (baseline: male) 
Female  0.82 0.68-0.99; p ~ 0.035 1.21 0.89-1.66 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.92 0.66-1.28 0.84 0.44-1.62 
25-34  1.00  1.00  
35-44 1.25 1.08-1.45; p ~ 0.002 1.81 1.40-2.32; p < 0.001 
45+ years 1.59 1.30-1.95; p < 0.001 2.93 2.15-3.99; p < 0.001 
Interaction between female & age-group at accrual (baseline: female & 25-34 years) 
< 25 years 0.61 0.36-1.05; p ~ 0.074 0.69 0.27-1.76 
25-34  1.00  1.00  
35-44 1.37 1.06-1.78; p ~ 0.016 1.34 0.90-2.00 
45+ years 1.46 1.02-2.10; p ~ 0.040 0.98 0.58-1.66 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
qQ1:       5 -   279 mg 1.00  1.00  
qQ2:   271 -   645 mg    0.99 0.83-1.19 0.98 0.72-1.33 
qQ3:   646 - 1120 mg    0.80 0.67-0.96; p ~ 0.015 0.78 0.57-1.07 
qQ4: 1121 - 1960 mg    0.83 0.70-0.99; p ~ 0.041 1.08 0.81-1.48; p ~ 0.001 
qQ5:        > 1960 mg    0.97 0.82-1.16 1.60 1.22-2.11; p ~ 0.001 
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Table A3: Proportional hazards regressions for Scotland’s restricted 2009-2015 CHI-
identified methadone-prescription cohort of 26,533 clients and 144,697 pys, with actual or 
recovered daily-dose of methadone prescribed at first CHI-identified methadone-
prescription. 
Quintiles for actual or recovered daily-dose of prescribed methadone at 1st CHI-identified 
prescription 
Events 
 
995 DRDs 420 Methadone-specific DRDs 
Covariates Hazard ratio (HR) 
95% CI for HR; p-value 
versus baseline 
Hazard 
ratio (HR) 
95% CI for HR; p-value 
versus baseline 
Prescription-source (baseline: GP-prescriber) 
Other-source 1.25 1.09-1.44; p ~ 0.001 1.32 1.07-1.63; p ~ 0.009 
Gender (baseline: male) 
Female 0.92 0.80-1.05 1.29 1.05-1.58; p ~ 0.013 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.70 0.50-0.97; p ~ 0.033 0.67 0.38-1.19 
25-34  1.00  1.00  
35-44 1.37 1.19-1.58; p< 0.001 2.00 1.60-2.50; p < 0.001 
45+ years 1.91 1.58-2.31; p <0.001 3.15 2.37-4.19; p < 0.001 
Quintiles for prescribed daily-dose at accrual (qQ1 as baseline) 
dQ1:   [1 -   34.5]    mg 1.00  1.00  
dQ2:   (34.5 -   50] mg    1.10 0.89-1.35 1.39 0.95-2.04 
dQ3    (50    -   70] mg 1.06 0.86-1.31 1.68 1.15-2.43; p ~ 0.007 
dQ4:   (70    -   90] mg  1.24 1.00-1.53; p ~ 0.046 2.16 1.49-3.13; p < 0.001 
dQ5:        > 90 mg    1.43 1.17-1.76; p ~ 0.001 3.15 2.21-4.48; p < 0.001 
Now including interaction for gender by age-group at accrual on 3 degrees of freedom (df) 
Interaction 
regression  
chi-squared on 3df 
 
11.13; p ~ 0.011 
 
6.52; p ~ 0.09 
Prescription-source (baseline: GP-prescriber) 
Other 1.26 1.09-1.44; p ~ 0.001 1.33 1.08-1.64; p ~ 0.008 
Gender (baseline: male) 
Female  0.78 0.63-0.98; p ~ 0.031 1.20 0.83-1.72 
Age-group at accrual (baseline: 25-34 years) 
< 25 years 0.92 0.62-1.38 1.02 0.49-2.13 
25-34  1.00  1.00  
35-44 1.23 1.04-1.46; p ~ 0.014 1.80 1.35-2.40; p < 0.001 
45+ years 1.76 1.40-2.20; p < 0.001 3.34 2.37-4.70; p < 0.001 
Interaction between female & age-group at accrual (baseline: female & 25-34 years) 
< 25 years 0.55 0.28-1.10 0.43 0.13-1.39 
25-34  1.00  1.00  
35-44 1.42 1.05-1.92; p ~ 0.023 1.33 0.84-2.10 
45+ years 1.32 0.86-2.02 0.78 0.42-1.47 
Quintiles for prescribed daily-dose at accrual (qQ1 as baseline) 
dQ1:   [1 -   34.5]    mg 1.00  1.00  
dQ2:   (34.5 -   50] mg    1.10 0.89-1.35 1.39 0.95-2.05 
dQ3    (50    -   70] mg 1.06 0.86-1.31 1.67 1.15-2.43; p ~ 0.007 
dQ4:   (70    -   90] mg  1.24 1.00-1.53; p ~ 0.048 2.15 1.49-3.12; p < 0.001 
dQ5:        > 90 mg    1.43 1.16-1.76; p < 0.001 3.15 2.21-4.47; p < 0.001 
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Appendix3: Sensitivity analyses 
Table A4: Proportional hazards regressions for Scotland’s restricted 2009-2015 CHI-identified 
methadone-prescription cohort of 26,533 clients and 144,697 pys, with actual or recovered daily-
dose of methadone prescribed at first CHI-identified methadone-prescription and current age-group. 
Quintiles for daily-dose of prescribed methadone at 1st CHI-identified prescription 
Events 
 
995 DRDs 420 Methadone-specific DRDs 
Covariates Hazard ratio (HR) 
95% CI for HR; p-
value versus baseline 
Hazard 
ratio (HR) 
95% CI for HR; p-
value versus baseline 
dQ regression, 4df Chi-square 16.34; p ~ 0.0026 Chi-square 58.59; p < 0.00001 
Prescription-source (baseline: GP-prescriber) 
Other-source 1.27 1.10-1.45; p ~ 0.001 1.34 1.08-1.65; p ~ 0.007 
Gender (baseline: male) 
Female 0.92 0.80-1.06 1.28 1.05-1.56; p ~ 0.016 
Current age-group (baseline: 25-34 years) 
< 25 years 0.71 0.43-1.16 0.58 0.23-1.43 
25-34  1.00  1.00  
35-44 1.36 1.16-1.58; p< 0.001 1.70 1.32-2.18; p < 0.001 
45+ years 2.10 1.77-2.50; p <0.001 3.15 2.40-4.13; p < 0.001 
Quintiles for prescribed daily-dose at accrual (dQ1 as baseline) 
dQ1:   [   1 -   35]  mg 1.00  1.00  
dQ2:   (35 -   50] mg    1.09 0.89-1.34 1.42 0.98-2.06 
dQ3    (50    - 70] mg 1.06 0.86-1.29 1.65 1.16-2.35; p ~ 0.006 
dQ4:   (70   -  90] mg  1.24 1.01-1.51; p ~ 0.043 2.11 1.49-3.01; p < 0.001 
dQ5:        > 90 mg    1.43 1.17-1.75; p < 0.001 3.10 2.22-4.33; p < 0.001 
Now including interaction for gender by current age-group on 3 degrees of freedom (df) 
Interaction regression, 3df Chi-square 10.18; p ~ 0.017 Chi-square 6.49; p ~ 0.090 
Prescription-source (baseline: GP-prescriber) 
Other 1.27 1.10-1.46; p ~ 0.001 1.34 1.08-1.65; p ~ 0.007 
Gender (baseline: male) 
Female  0.70 0.54-0.91; p ~ 0.007 1.06 0.70-1.60 
Current age-group (baseline: 25-34 years) 
< 25 years 0.93 0.51-1.72 1.16 0.42-3.20 
25-34  1.00  1.00  
35-44 1.18 0.99-1.42 1.46 1.06-2.01; p ~ 0.020 
45+ years 1.84 1.50-2.26; p < 0.001 2.97 2.12-4.16; p < 0.001 
Interaction between female & current age-group (baseline: female & 25-34 years) 
< 25 years 0.58 0.21-1.61 0.18 0.02-1.65 
25-34  1.00  1.00  
35-44 1.52 1.09-2.11; p ~ 0.013 1.46 0.88-2.43 
45+ years 1.52 1.05-2.22; p ~ 0.028 1.12 0.64-1.97 
Quintiles for prescribed daily-dose at accrual (dQ1 as baseline) 
dQ1:   [1 -   34.5]    mg 1.00  1.00  
dQ2:   (34.5 -   50] mg    1.09 0.89-1.34 1.42 0.97-2.06 
dQ3    (50    -   70] mg 1.06 0.86-1.29 1.65 1.15-2.35; p ~ 0.006 
dQ4:   (70    -   90] mg  1.23 1.01-1.51; p ~ 0.045 2.11 1.48-3.00; p < 0.001 
dQ5:        > 90 mg    1.43 1.17-1.74; p < 0.001 3.10 2.22-4.33; p < 0.001 
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Table A5: Proportional hazards regressions for Scotland’s restricted 2009-2015 CHI-identified 
methadone-prescription cohort of 19,184 GP-clients and 107,284 pys, with actual or recovered daily-
dose of methadone prescribed at first CHI-identified methadone-prescription and current age-group. 
Quintiles for daily-dose of prescribed methadone at 1st CHI-identified prescription for GP-clients 
Events 
 
706 DRDs 293 Methadone-specific DRDs 
Covariates Hazard ratio (HR) 
95% CI for HR; p-
value versus baseline 
Hazard 
ratio (HR) 
95% CI for HR; p-
value versus baseline 
dQ regression, 4df Chi-square 14.45; p ~ 0.0060 Chi-square 44.60; p < 0.00001 
Gender (baseline: male) 
Female 0.91 0.78-1.08 1.38 1.09-1.76; p ~ 0.008 
Current age-group (baseline: 25-34 years) 
< 25 years 0.79 0.43-1.46 0.58 0.18-1.86 
25-34  1.00  1.00  
35-44 1.30 1.08-1.57; p ~ 0.005 1.49 1.10-2.00; p ~ 0.009 
45+ years 1.91 1.55-2.34; p <0.001 2.57 1.86-3.54; p < 0.001 
Quintiles for prescribed daily-dose at accrual (dQ1 as baseline) 
dQ1:   [   1 -   35]  mg 1.00  1.00  
dQ2:   (35 -   50] mg    1.16 0.92-1.46 1.60 1.02-2.51; p ~ 0.040 
dQ3    (50    - 70] mg 0.92 0.72-1.18 1.81 1.16-2.82; p ~ 0.009 
dQ4:   (70   -  90] mg  1.07 0.83-1.38 2.01 1.28-3.15; p ~ 0.003 
dQ5:        > 90 mg    1.40 1.10-1.77; p ~ 0.005 3.45 2.27-5.23; p < 0.001 
Now including interaction for gender by current age-group on 3 degrees of freedom (df) 
Interaction regression, 3df Chi-square 9.43; p ~ 0.024 Chi-square 5.19; p ~ 0.158 
Gender (baseline: male) 
Female  0.63 0.45-0.87; p ~ 0.005 0.90 0.54-1.50 
Current age-group (baseline: 25-34 years) 
< 25 years 0.96 0.45-2.06 0.89 0.22-3.70 
25-34  1.00  1.00  
35-44 1.11 0.89-1.38 1.16 0.80-1.69 
45+ years 1.60 1.26-2.04; p < 0.001 2.11 1.42-3.13; p < 0.001 
Interaction between female & current age-group (baseline: female & 25-34 years) 
< 25 years 0.72 0.20-2.57 0.44 0.04-5.16 
25-34  1.00  1.00  
35-44 1.67 1.11-2.50; p ~ 0.013 1.86 1.00-3.43; p ~ 0.049 
45+ years 1.78 1.13-2.81; p ~ 0.012 1.65 0.85-3.23 
Quintiles for prescribed daily-dose at accrual (dQ1 as baseline) 
dQ1:   [1 -   34.5]    mg 1.00  1.00  
dQ2:   (34.5 -   50] mg    1.16 0.92-1.46 1.60 1.02-2.51; p ~ 0.040 
dQ3    (50    -   70] mg 0.93 0.72-1.19 1.81 1.16-2.82; p ~ 0.009 
dQ4:   (70    -   90] mg  1.07 0.83-1.37 2.00 1.27-3.13; p ~ 0.003 
dQ5:        > 90 mg    1.39 1.10-1.76; p ~ 0.006 3.44 2.27-5.22; p < 0.001 
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Table A6:  Proportional hazards regression for methadone-specific DRDs: 16,350 clients in Scotland’s 2009-
2015 CHI-identified methadone-prescription cohort with actual or recovered daily-dose of methadone at first 
CHI-identified methadone-prescription and cohort-entry in July to December 2009; 102,566 pys of follow-up. 
Quintiles for actual or recovered daily-dose of methadone at 1st CHI-identified prescription (dQ) 
dQ regression chi-square of 49.31 on 4 degrees of freedom; p < 0.00001 
Events 295 Methadone-specific DRDs 
Covariates               [clients, %] Hazard Ratio (HR) 95% confidence interval for HR; p-value versus baseline 
Prescription-source (baseline: GP-prescriber) 
Other-source          [3036, 19%] 1.00 0.74-1.35;     p ~ 0.995 
Gender (baseline: male) 
Female                     [5502, 34%] 1.28 1.01-1.63;     p ~ 0.040 
Age-group at accrual (baseline: 25-34 years) 
< 25 years                [   796,  5%] 0.29 0.09-0.93;     p ~ 0.037 
25-34                        [7105, 43%] 1.00 Baseline 
35-44                        [6717, 41%] 1.71 1.32-2.23;     p < 0.001 
45+ years                 [1732, 11%] 2.59 1.84-3.65;     p < 0.001 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
dQ1:   [1 -   34.5]    mg   [2608, 16%] 1.00 Baseline 
dQ2:   (34.5 -   50] mg   [3394, 21%] 1.80 1.07-3.04;     p ~ 0.028 
dQ3    (50    -   70] mg    [3768, 23%] 2.18 1.32-3.61;     p ~ 0.002 
dQ4:   (70    -   90] mg    [3253, 20%] 2.45 1.48-4.06;     p ~ 0.001 
dQ5:        > 90 mg        [3327, 20%] 4.03 2.50-6.52;     p < 0.001 
 
Table A7:  Proportional hazards regression for methadone-specific DRDs: 10,183 clients Scotland’s 2009-
2015 CHI-identified methadone-prescription cohort with actual or recovered daily-dose of methadone at first 
CHI-identified methadone-prescription and cohort-entry after 2009; 42,131 pys of follow-up. 
Quintiles for actual or recovered daily-dose of methadone at 1st CHI-identified prescription (dQ) 
dQ regression chi-square of 16.20 on 4 degrees of freedom; p ~ 0.0028 
Events 125 Methadone-specific DRDs 
Covariates               [clients, %] Hazard Ratio (HR) 95% confidence interval for HR; p-value versus baseline 
Prescription-source (baseline: GP-prescriber) 
Other-source          [4313, 42%] 1.80 1.25-2.61;     p ~ 0.002 
Gender (baseline: male) 
Female                     [3242, 32%] 1.35 0.93-1.96;     p ~ 0.116 
Age-group at accrual (baseline: 25-34 years) 
< 25 years                [1195, 12%] 1.24 0.60-2.54;    p ~ 0.564 
25-34                        [4462, 44%] 1.00 Baseline 
35-44                        [3337, 33%] 2.92 1.88-4.54;    p < 0.001 
45+ years                 [1189, 12%] 4.97 2.92-8.44;    p < 0.001 
Quintiles for prescribed quantity at accrual (qQ1 as baseline) 
dQ1:   [1 -   34.5]    mg   [2699, 27%] 1.00 Baseline 
dQ2:   (34.5 -   50] mg   [2893, 28%] 0.97 0.54-1.74;   p ~ 0.910 
dQ3    (50    -   70] mg   [2124, 21%] 1.11 0.61-2.02;   p ~ 0.733 
dQ4:   (70    -   90] mg   [1392, 14%] 2.08 1.17-3.68;   p ~ 0.012 
dQ5:        > 90 mg         [1075, 11%] 2.25 1.25-4.05;   p ~ 0.007 
 
